Skip to main content

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.

Publication ,  Journal Article
Addington, DE; Mohamed, S; Rosenheck, RA; Davis, SM; Stroup, TS; McEvoy, JP; Swartz, MS; Lieberman, JA
Published in: J Clin Psychiatry
January 2011

BACKGROUND: According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), conducted between January 2001 and December 2004. METHOD: Patients with DSM-IV-defined schizophrenia (N = 1,460) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of 4 second-generation drugs (olanzapine, quetiapine, risperidone, or ziprasidone) and followed for up to 18 months (phase 1). Patients with tardive dyskinesia were excluded from the randomization that included perphenazine. Depression was assessed with the Calgary Depression Scale for Schizophrenia (CDSS). Mixed models were used to evaluate group differences during treatment with the initially assigned drug. An interaction analysis evaluated differences in drug response by whether patients had a baseline score on the CDSS of ≥ 6, indicative of a current major depressive episode (MDE). RESULTS: There were no significant differences between treatment groups on phase 1 analysis, although there was a significant improvement in depression across all treatments. A significant interaction was found between treatment and experiencing an MDE at baseline (P = .05), and further paired comparisons suggested that quetiapine was superior to risperidone among patients who were in an MDE at baseline (P = .0056). CONCLUSIONS: We found no differences between any second-generation antipsychotic and the first-generation antipsychotic perphenazine and no support for the clinical practice recommendation, but we did detect a signal indicating a small potential difference favoring quetiapine over risperidone only in patients with an MDE at baseline.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Psychiatry

DOI

EISSN

1555-2101

Publication Date

January 2011

Volume

72

Issue

1

Start / End Page

75 / 80

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Schizophrenic Psychology
  • Schizophrenia
  • Psychiatry
  • Perphenazine
  • Middle Aged
  • Male
  • Longitudinal Studies
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Addington, D. E., Mohamed, S., Rosenheck, R. A., Davis, S. M., Stroup, T. S., McEvoy, J. P., … Lieberman, J. A. (2011). Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry, 72(1), 75–80. https://doi.org/10.4088/JCP.09m05258gre
Addington, Donald E., Somaia Mohamed, Robert A. Rosenheck, Sonia M. Davis, Thomas Scott Stroup, Joseph P. McEvoy, Marvin S. Swartz, and Jeffrey A. Lieberman. “Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.J Clin Psychiatry 72, no. 1 (January 2011): 75–80. https://doi.org/10.4088/JCP.09m05258gre.
Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, et al. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry. 2011 Jan;72(1):75–80.
Addington, Donald E., et al. “Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.J Clin Psychiatry, vol. 72, no. 1, Jan. 2011, pp. 75–80. Pubmed, doi:10.4088/JCP.09m05258gre.
Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry. 2011 Jan;72(1):75–80.

Published In

J Clin Psychiatry

DOI

EISSN

1555-2101

Publication Date

January 2011

Volume

72

Issue

1

Start / End Page

75 / 80

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Schizophrenic Psychology
  • Schizophrenia
  • Psychiatry
  • Perphenazine
  • Middle Aged
  • Male
  • Longitudinal Studies
  • Humans
  • Female